Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21197351 | 0.99 | USP30 (0.43) | USP30USP2SMN1; SMN2ESR2CYP11B2 | |
| SCHEMBL21197226 | 0.97 | USP30 (0.44) | USP30USP2SMN1; SMN2ESR2CYP11B2 | |
| SCHEMBL2158895 | 0.94 | USP30 (0.46) | USP30USP2SMN1; SMN2ESR2CYP11B2 | |
| SCHEMBL31645803 | 0.92 | USP30 (0.42) | USP30USP2SMN1; SMN2CYP11B2NR1H2 | |
| SCHEMBL31171500 | 0.92 | USP30 (0.47) | USP30USP2SMN1; SMN2CYP11B2NR1H2 | |
| SCHEMBL31171576 | 0.90 | USP30 (0.48) | USP30USP2SMN1; SMN2CYP11B2NR1H2 | |
| SCHEMBL31566861 | 0.90 | USP30 (0.48) | USP30USP2SMN1; SMN2CYP11B2NR1H2 | |
| SCHEMBL26378530 | 0.90 | USP30 (0.43) | USP30USP2SMN1; SMN2ESR2CYP11B2 | |
| SCHEMBL31567024 | 0.90 | USP30 (0.48) | USP30USP2SMN1; SMN2CYP11B2NR1H2 | |
| SCHEMBL21197057 | 0.87 | USP2 (0.51) | USP30USP2SMN1; SMN2ESR2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | ALMAC DISCOVERY LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| EP-4313295-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157285-A | Pharmaceutical compounds as ubiquitin-specific protease 19 (USP 19) inhibitors | 阿尔麦克探索有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| WO-2022200523-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-02-16 | — | — | WO | disclosed |
| EP-3746432-B1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022200523-A1 | PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2022-09-29 | — | — | WO | disclosed |
| CN-109790146-B | Pharmaceutical compounds | 阿尔麦克探索有限公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-3490982-B1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2021-03-11 | — | — | US | disclosed |
| CN-112135818-A | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2020-12-25 | — | — | CN | disclosed |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2019-08-01 | — | — | US | disclosed |
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006113458-A1 | HETEROCYCLIC INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2006-10-19 | — | — | US | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| EP-1487822-A2 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003076398-A2 | PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327382-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 | USP19, USP18, UBE2I | USP30 56/4885USP2 6/4885SMN1; SMN2 2749/4885 |
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | USP30 57/4885USP2 7/4885SMN1; SMN2 2586/4885 |
| US-20190233394-A1 | PHARMACEUTICAL COMPOUNDS | USP19, USP18, UBE2I | USP30 57/4885USP2 7/4885SMN1; SMN2 2586/4885 |
| US-20060235037-A1 | Heterocyclic inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT8 | USP30 1388/4885USP2 1422/4885SMN1; SMN2 3916/4885 |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | USP30 64/4885USP2 6/4885SMN1; SMN2 561/4885 |
| US-20210070773-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | USP30 64/4885USP2 6/4885SMN1; SMN2 561/4885 |
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | USP30 1748/4885USP2 2050/4885SMN1; SMN2 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.